Claims
- 1. A combination of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is a selective 5-HT.sub.1A antagonist of the formula ##STR7## wherein R.sub.1 is n-propyl or cyclobutyl;
- R.sub.2 is isopropyl, tertiary butyl, cyclobutyl, cyclopentyl or cyclohexyl;
- R.sub.3 is hydrogen;
- R.sub.4 is hydrogen or methyl;
- said 5-HT.sub.1A -antagonist being in the form of its R-enantiomer, and said components (a) and (b) being in the form of their free bases or pharmaceutically acceptable salts thereof.
- 2. The combination according to claim 1 wherein the selective 5-HT.sub.1A antagonist is (R)-3-(N-tert-butyl-N-n-propylamino)-5-carbamoyl-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof.
- 3. The combination according to claim 1 wherein the 5-HT.sub.1A antagonist is (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof.
- 4. The combination according to claim 1 wherein the 5-HT.sub.1A antagonist is (R)-5-carbamoyl-3-(N-cyclobutyl-N-n-propylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof.
- 5. The combination according to claim 1 wherein the 5-HT.sub.1A antagonist is (R)-5-carbamoyl-3-(N-cyclobutyl-N-isopropylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof.
- 6. The combination according to claim 1 wherein the 5-HT.sub.1A antagonist is (R)-5-carbamoyl-3-(N-cyclopentyl-N-n-propylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof.
- 7. The combination according to claim 1 wherein the 5-HT.sub.1A antagonist is (R)-5-carbamoyl-3-(N-cyclopentyl-N-cyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof.
- 8. The combination according any one of claims 1-7 wherein the 5-HT reuptake inhibitor is fluoxetine.
- 9. A process for the preparation of a combination of a 5-HT reuptake inhibitor and a selective 5-HT.sub.1A antagonist, which comprises incorporating a 5-HT reuptake inhibitor into the same pharmaceutical formulation as a selective 5-HT.sub.1A antagonist as defined in any one of claims 1-7.
- 10. A process for the preparation of a combination of a 5-HT reuptake inhibitor and a selective 5-HT.sub.1A antagonist whereby a 5-HT reuptake inhibitor in a first pharmaceutical formulation is combined with a selective 5-HT.sub.1A antagonist as defined in any one of claims 1-7 in a second pharmaceutical formulation.
- 11. A kit containing the combination of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is a selective 5-HT.sub.1A antagonist according to claim 1 optionally with instructions for use.
- 12. A method of improving the onset of therapeutic action which comprises coadministration of a first component (a) which is a 5-HT reuptake inhibitor and a second component (b) which is a selective 5-HT.sub.1A antagonist as described in claim 1.
- 13. The combination according to any one of claims 1-7 wherein the 5-HT reuptake inhibitor is paroxetine.
- 14. The combination according to any one of claims 1-7 wherein the 5-HT reuptake inhibitor is citalopram.
- 15. The combination according to any one of claims 1-7 wherein the 5-HT reuptake inhibitor is clomipramine.
- 16. The combination according to any one of claims 1-7 wherein the 5-HT reuptake inhibitor is sertraline.
- 17. The combination according to any one of claims 1-7 wherein the 5-HT reuptake inhibitor is fluvoxamine.
- 18. The combination of the selective 5-HT.sub.1A antagonist (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof and the 5-HT reuptake inhibitor fluoxetine.
- 19. The combination of the selective 5-HT.sub.1A antagonist (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof and the 5-HT reuptake inhibitor paroxetine.
- 20. The combination of the selective 5-HT.sub.1A antagonist (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof and the 5-HT reuptake inhibitor citalopram.
- 21. The combination of the selective 5-HT.sub.1A antagonist (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof and the 5-HT reuptake inhibitor clomipramine.
- 22. The combination of the selective 5-HT.sub.1A antagonist (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof and the 5-HT reuptake inhibitor sertraline.
- 23. The combination of the selective 5-HT.sub.1A antagonist (R)-5-carbamoyl-3-(N,N-dicyclobutylamino)-8-fluoro-3,4-dihydro-2H-1-benzopyran in the form of its free base or a pharmaceutically acceptable salt thereof and the 5-HT reuptake inhibitor fluvoxamine.
- 24. A method for the treatment of affective disorders which comprises administering to a patient suffering therefrom an effective amount of the combination defined in any one of claims 1-7 and 18-23.
- 25. A method for the treatment of depression which comprises administering to a patient suffering therefrom an effective amount of the combination defined in any one of claims 1-7 and 18-23.
- 26. A pharmaceutical formulation for use in the treatment of affective disorders wherein the active ingredients are the combination defined in any one of claims 1-7 and 18-23 optionally with diluents, excipients and/or inert carriers.
- 27. A pharmaceutical formulation according to claim 26 for use in the treatment of depression.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9501567 |
Apr 1995 |
SEX |
|
Parent Case Info
This application is a 371 of PCT/SE96/00526 filed Apr. 23, 1996.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
102e Date |
371c Date |
PCT/SE96/00526 |
4/23/1996 |
|
|
5/9/1996 |
5/9/1996 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO96/33710 |
10/31/1996 |
|
|
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4698342 |
Crosby |
Oct 1987 |
|
5616610 |
Evenden et al. |
Apr 1997 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
WO9511891 |
May 1995 |
WOX |
Non-Patent Literature Citations (1)
Entry |
Artigas, et al., Arch. Gen. Psychiatry 51, 248-251 (1994). |